Multiple Sclerosis, Chronic Progressive
A form of multiple sclerosis characterized by a progressive deterioration in neurologic function which is in contrast to the more typical relapsing remitting form. If the clinical course is free of distinct remissions, it is referred to as primary progressive multiple sclerosis. When the progressive decline is punctuated by acute exacerbations, it is referred to as progressive relapsing multiple sclerosis. The term secondary progressive multiple sclerosis is used when relapsing remitting multiple sclerosis evolves into the chronic progressive form. (From Ann Neurol 1994;36 Suppl:S73-S79; Adams et al., Principles of Neurology, 6th ed, pp903-914)
Drugs by status
Approved for this indication (4)
Phase 4 trials (1)
Phase 3 trials (20)
Phase 2 trials (32)
- simvastatin
- metformin
- corticotropin
- acetylcysteine
- baminercept
- lamotrigine
- hydroxychloroquine
- insulin human
- hyperimmune caprine serum
- ibudilast
- idebenone
- indapamide
- laquinimod
- fluoxetine
- mis416
- progestin
- riluzole
- tovaxin
- clemastine
- imilecleucel-t
- autologous mesenchymal stem cells
- domperidone
- amiloride
- Andrographis paniculata
- amniotic fluid
- estriol
- norethindrone
- foralumab
- nurown
- och-ncnp1
- +2 more
Phase 1 trials (19)
- autologous vitd3 tolerogenic monocyte-derived dendritic cells loaded with a pool of myelin peptides
- methylphenidate
- duoc-01
- aldesleukin
- ixazomib
- gadoteridol
- rtl1000
- ferumoxytol
- cd19 car-t cells
- autologous mesenchymal stem cell-derived neural progenitors
- mesna
- autologous cd34+ cells transduced withpsrs11.efs.il2rg.pre
- fludarabine
- liothyronine
- peginterferon beta-1a
- [f-18]sdm-8
- idp-023
- pipe-791
- allogenic placenta derived mesenchymal stem cells
Organizations
Organization Involved with Phase 4 Indications (1)
Organization Involved with Phase 3 Indications (30)
- AB Science
- Eli Lilly
- Genentech
- Pfizer
- Sanofi
- Biogen
- Wyeth
- Novartis
- Bayer
- BioMS Technology Corp.
- Region Syddanmark
- Aarhus University
- University of Pennsylvania
- Central Jutland Regional Hospital
- University of London
- Oregon Health and Science University
- University of Edinburgh
- University of Leeds
- University of Southern Denmark
- University of Bordeaux
- Aalborg University
- University of Copenhagen
- Hospital of South West Jutland
- Isfahan University
- Department of Veteran Affairs
- Government of France
- Assistance Publique - Hôpitaux de Paris
- ICM - Brain & Spine Institute
- Danske Regioner
- Hospital of Central Denmark Region, Viborg, Denmark
Organization Involved with Phase 2 Indications (39)
- MediciNova
- Brainstorm Cell Therapeutics
- Daval International Limited
- INC Research
- Innate Immunotherapeutics
- Innobioscience SpA
- Mallinckrodt
- Mapi Pharma Ltd.
- Teva
- National Institutes of Health (NIH)
- Medical Research Council
- National Center of Neurology and Psychiatry, Japan
- National Institute of Neurological Disorders and Stroke (NINDS)
- Banc de Sang i Teixits
- Centre Hospitalier de PAU
- Keele University
- Johns Hopkins University
- Pontificia Universidad Catolica de Chile
- Sheffield Hallam University
- Universidad Austral de Chile
- University of Rochester
- University of Warwick
- Tel Aviv University
- University of Calgary
- University of California, Los Angeles
- University of Chile
- University of Minnesota
- CH Pau
- Universidad Autonoma de Barcelona
- Primorus Clinical Trials
- +9 more
Organization Involved with Phase 1 Indications (23)
- Takeda
- Elan Pharmaceuticals
- Artielle ImmunoTherapeutics
- Atara Biotherapeutics
- Casa Sollievo della Sofferenza IRCCS
- Case Western Reserve University
- Harvard University
- Indiana University
- University of Iowa
- University of Kansas
- University of Maryland
- University of Michigan
- Yale University
- University of Utah
- Badalona Hospital Germans Trias i Pujol
- Neurocenter of Southern Switzerland, Lugano
- Clinica Universidad de Navarra
- DJO Incorporated
- Pinnaclife Inc.
- TZ Press, LLC
- EvergreenHealth
- Revert ONLUS
- Fondazione Cellule Staminali
Organization Involved with Other Experimental Indications (1)